SCHEMBL24665357

SCHEMBL24665357

N[C@H](CO)Cc1nc(-c2cccc(Oc3ccc(Cl)cn3)c2)no1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 3/20 0.58
▸ KCNH2 Q12809 1/20 0.58
▸ SCN5A Q14524 2/20 0.43
▸ SCN10A Q9Y5Y9 2/20 0.43
▸ MAPT P10636 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ TDP1 Q9NUW8 4/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ FFAR1 O14842 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NOTUM Q6P988 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27204649 1.00 LTA4H (0.58) LTA4HKCNH2SCN5ASCN10AMAPT
SCHEMBL27171426 0.88 LTA4H (0.70) LTA4HKCNH2SCN5ASCN10AMAPT
SCHEMBL27204696 0.88 LTA4H (0.70) LTA4HKCNH2SCN5ASCN10AMAPT
SCHEMBL29123324 0.86 LTA4H (0.54) LTA4HKCNH2MAPTMAPK1FFAR1
SCHEMBL24664170 0.86 LTA4H (0.54) LTA4HKCNH2MAPTMAPK1FFAR1
SCHEMBL24665376 0.86 LTA4H (0.56) LTA4HKCNH2SCN5ASCN10AMAPT
SCHEMBL29123411 0.86 LTA4H (0.56) LTA4HKCNH2SCN5ASCN10AMAPT
SCHEMBL29123584 0.86 LTA4H (0.43) LTA4HKCNH2MAPTSMN1; SMN2TDP1
SCHEMBL29123582 0.86 LTA4H (0.43) LTA4HKCNH2MAPTSMN1; SMN2TDP1
SCHEMBL24665397 0.83 LTA4H (0.82) LTA4HKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4323062-B1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2025-07-23 — — EP claimed
CN-117015537-A Heteroaryl aminopropanol derivatives as inhibitors of LTA4H 诺华股份有限公司 2023-11-07 — — CN claimed
US-11932630-B2 Heteroaryl aminopropanol derivatives NOVARTIS AG (CH) 2024-03-19 — — US disclosed
EP-4323062-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H Novartis AG (CH) 2024-02-21 — — EP disclosed
CN-117015537-A Heteroaryl aminopropanol derivatives as inhibitors of LTA4H 诺华股份有限公司 2023-11-07 — — CN disclosed
WO-2022219546-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2022-10-20 — — WO disclosed
WO-2022219546-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2022-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932630-B2 Heteroaryl aminopropanol derivatives CYP3A43, CYP11B2, ADRB3 LTA4H 1006/4885KCNH2 1449/4885SCN5A 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback